Jim Tananbaum Continues to Surprise Many in the Healthcare Sector

Jim Tananbaum is a rarity. It is not often that you come across a man barely in his fifties with close to three decades of investing experience, let alone successful investments in 21 companies. However, Jim Tananbaum has achieved that and more. The current CEO of Foresite Capital Management has over the last 26 years been among the leading investors in the healthcare industry, handling billions of dollars in the process.

Jim Tananbaum has been able to achieve all this because he hit the ground running. He joined Yale University at the tender age of 18 to complete a B.S.S.E degree. By the age of 27, he received a Doctor of Medicine degree from Harvard Medical School and an M.S degree in Health Sciences and Technology from the famed Massachusetts Institute of Technology. Finally, in 1991, aged only 29, he received his final academic qualification, an MBA from Harvard Business School.

According to Market Wired, if you though Jim Tananbaum’s academic endeavors are astounding, wait till you hear about his professional journey. Straight after leaving Harvard, Tananbaum invested in GelTex Pharmaceuticals. While at the helm the company introduced two revolutionary drugs, Cholestagel and Ranagel, which drove its revenues up to the tune of billions. Industry players took note, and the company was purchased by Genzyme in 1992 for $1.6 billion. His next two investment undertakings were equally successful with Sierra Partners leading investments in Care Select and Amerigroup while Theravance grew its market capitalization to about $3.5 billion. A lengthy stint at Prospect Venture Partners, a company he co-founded, then set the tone for him forming and leading Foresite Capital. Visit Ideamensch to know more.

Owing to his academic prowess and professional success, Jim Tananbaum has been invited to serve in advisory capacities at the Ivy League institutions at which he studied. At Yale, he is part of the president’s advisory board. On the other hand, at Harvard, he is an advisor to the Harvard-MIT health sciences and technology program.

Fortunately for the healthcare industry, it does not look like Tananbaum is slowing down anytime soon. At Foresite Capital Management he has assets valued at $1.1 billion under his management. Hopefully, he will, over the coming years, continue to healthcare companies that will guarantee a healthier and safer public.

Read more: http://www.massdevice.com/neuropsych-treatment-diagnosis-platform-dev-mindstrong-health-raises-14m-series/